Versant Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Versant Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-473	Closed	-$14.9K	–	2817
2026 Q2	$14.9K	Buy	473 +255	+117%	+$7.53K	﹤0.01%	2079
2026 Q1	$5.4K	Buy	218 +205	+1,577%	+$4.88K	﹤0.01%	2357
2025 Q4	$303	Hold	13	–	–	﹤0.01%	2607
2025 Q3	$256	Hold	13	–	–	﹤0.01%	2598
2025 Q2	$282	Hold	13	–	–	﹤0.01%	2580
2025 Q1	$315	Hold	13	–	–	﹤0.01%	2442
2024 Q4	$271	Hold	13	–	–	﹤0.01%	2318
2024 Q3	$258	Hold	13	–	–	﹤0.01%	1944
2024 Q2	$201	Hold	13	–	–	﹤0.01%	1905
2024 Q1	$207	Hold	13	–	–	﹤0.01%	1828
2023 Q4	$219	Hold	13	–	–	﹤0.01%	1856
2023 Q3	$152	Hold	13	–	–	﹤0.01%	1899
2023 Q2	$175	Buy	+13	New	+$187	﹤0.01%	2001

Other funds holding CPRX

Teacher Retirement System of Texas Austin, Texas $37.3B AUM 26.21% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Versant Capital Management's CPRX Position: Q3 2026 in Review

Versant Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 473 shares — an estimated $14.9K sold.

Versant Capital Management first reported a position in CPRX in Q2 2023 and held it in 13 quarters. The position peaked at $14.9K in Q2 2026. 3 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

Versant Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Versant Capital Management sold 473 Catalyst Pharmaceutical shares in Q3 2026, an estimated $14.9K.
Versant Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 13 quarters.
Versant Capital Management's Catalyst Pharmaceutical position peaked at $14.9K in Q2 2026.
3 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.